Boehringer Ingelheim and Duke Research Institute Expand IPF Patient Registry
News
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) are expanding the Idiopathic Pulmonary Fibrosis PROspective Outcomes Registry (IPF-PRO), which they say will make it the largest IPF patient registry in the country. The ... Read more